公开(公告)号：US10280205B2

公开(公告)日：2019-05-07

申请号：US15198853

申请日：2016-06-30

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K14/74 ,  A61K39/00 ,  C12N15/115 ,  C07K7/08 ,  C07K7/06 ,  C07K16/28 ,  C12N5/0783 ,  A61K35/17 ,  C07K16/30 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/569 ,  C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/705 ,  C07K16/18 ,  A61K38/00 ,  A61K35/12

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10174089B2

公开(公告)日：2019-01-08

申请号：US15980328

申请日：2018-05-15

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C12N15/115 ,  C07K7/08 ,  C07K7/06 ,  C07K16/28 ,  C12N5/0783 ,  A61K35/17 ,  C07K16/30 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/569 ,  C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/705 ,  C07K16/18 ,  A61K38/00 ,  A61K35/12

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180303919A1

公开(公告)日：2018-10-25

申请号：US16024133

申请日：2018-06-29

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61K38/17 ,  C07K7/06 ,  C07K14/47 ,  C07K14/725 ,  C07K16/28 ,  C12N15/115 ,  A61P35/02

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K38/08 ,  A61K38/1709 ,  A61K39/39 ,  A61K2039/5158 ,  A61P35/02 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/2833 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12226466B2

公开(公告)日：2025-02-18

申请号：US17333902

申请日：2021-05-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K38/00 ,  A61K35/17 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61P35/00 ,  A61P35/02 ,  C07K7/06 ,  C07K14/47 ,  C07K14/72 ,  C07K14/725 ,  C07K16/00 ,  C07K16/28 ,  C12N15/115 ,  A61K39/39 ,  C07K7/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220064240A1

公开(公告)日：2022-03-03

申请号：US17530443

申请日：2021-11-18

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K14/74 ,  A61K39/00 ,  C12N15/115 ,  C07K7/08 ,  C07K7/06 ,  C07K16/28 ,  C12N5/0783 ,  A61K35/17 ,  C07K16/30 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/569 ,  C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/705 ,  C07K16/18

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10464978B2

公开(公告)日：2019-11-05

申请号：US15199244

申请日：2016-06-30

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K38/00 ,  A61K35/12 ,  C07K14/47 ,  C07K14/74 ,  A61K39/00 ,  C12N15/115 ,  C07K7/08 ,  C07K7/06 ,  C07K16/28 ,  C12N5/0783 ,  A61K35/17 ,  C07K16/30 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/569 ,  C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/705 ,  C07K16/18

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190091312A1

公开(公告)日：2019-03-28

申请号：US16210357

申请日：2018-12-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K38/08 ,  A61K38/1709 ,  A61K39/39 ,  A61K2039/5158 ,  A61K2039/812 ,  A61P35/00 ,  A61P35/02 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/721 ,  C07K16/00 ,  C07K16/2833 ,  C07K2317/41 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10238728B2

公开(公告)日：2019-03-26

申请号：US16177919

申请日：2018-11-01

Applicant: Immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  A61K38/17 ,  C07K7/06 ,  C07K14/725 ,  C07K14/47 ,  C12N15/115 ,  C07K16/28 ,  A61K38/08 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10143733B2

公开(公告)日：2018-12-04

申请号：US16024142

申请日：2018-06-29

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K35/17 ,  A61K39/00 ,  A61K38/17 ,  C07K7/06 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  A61P35/02 ,  C07K16/28 ,  A61K38/08

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10047131B2

公开(公告)日：2018-08-14

申请号：US15198540

申请日：2016-06-30

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K35/17 ,  C07K14/47 ,  C07K14/74 ,  A61K39/00 ,  C12N15/115 ,  C07K7/08 ,  C07K7/06 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/30 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/569 ,  C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/705 ,  C07K16/18 ,  A61K38/00 ,  A61K35/12

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4705 ,  C07K14/4738 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/30 ,  C12N2501/50 ,  C12N2501/998 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/56977 ,  G01N33/57449 ,  G01N33/57492 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.